Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-04
2005-10-04
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000, C530S322000
Reexamination Certificate
active
06951840
ABSTRACT:
Provided are novel lipoglycopeptides exhibiting bacterial signal peptidase inhibitory activity. Also provided are actinomycete strains that produce these lipoglycopeptides, methods of producing such lipoglycopeptides by culturing these strains, pharmaceutical compositions comprising these lipoglycopeptides, and methods of treating bacterial infections comprising contacting bacteria susceptible to treatment with the present bacterial signal peptidase inhibitor lipoglycopeptides. These lipoglycopeptides are useful in human and veterinary medicine.
REFERENCES:
Schmid, D.G. et al. P368 Biaryl-bridged lipopeptides from aStreptomycessp. TU 6075, 2nd International Symposium/17th American Peptide Symposium, San Diego, Jun. 9-14, 2001.
Belvo Matthew David
Kreuzman Adam Joseph
Kulanthaivel Palaniappan
Peng Sheng-Bin
Smitka Tim Allen
Eli Lilly and Company
Lilling Herbert J.
LandOfFree
Lipoglycopeptide antibiotics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoglycopeptide antibiotics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoglycopeptide antibiotics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486896